Eli Lilly has acquired San Carlos, California-based Engage Biologics Inc. for up to USD 202 million in cash, adding the company's Tethosome non-viral DNA delivery platform to its genetic medicines portfolio. The Indianapolis-based pharmaceutical company structured the deal as an upfront cash payment plus contingent payments tied to specified development milestones, though the breakdown between the two components was not disclosed.
Engage Bio, founded in 2021 and backed by seed investors including Y Combinator and the Cystic Fibrosis Foundation, as well as non-dilutive funding from the Gates Foundation and NIH-NCATS, remained at the preclinical stage at the time of acquisition. The Tethosome platform combines engineered DNA payloads with lipid nanoparticle delivery and a proprietary mRNA-encoded technology designed to improve nuclear localization and increase gene expression. The company described the system as addressing two core barriers that have constrained non-viral DNA delivery: nuclear localization and innate immune sensing. DNA payloads are further engineered to reduce immunogenicity while retaining the durability and programmability associated with DNA-based approaches.
No specific lead asset, internal program code, or clinical trial was disclosed as central to the transaction. The acquisition was framed at the platform level, with Lilly citing the potential to integrate Tethosome's capabilities with its existing genetic medicine infrastructure. Financial terms beyond the USD 202 million ceiling were not disclosed, and no royalty provisions, equity components, or commercial milestones were described in the announcement. Geographic rights were not separately specified; as a full company acquisition, Lilly would be expected to hold global rights to all of Engage's intellectual property and pipeline assets.
The deal represents Lilly's second platform-level acquisition in the non-viral genetic medicines space within a four-month period. In February 2026, Lilly acquired Orna Therapeutics for up to USD 2.4 billion, adding an engineered circular RNA platform paired with lipid nanoparticle delivery focused on in vivo cell engineering. The value differential between the two deals — USD 202 million for Engage versus USD 2.4 billion for Orna — is consistent with Engage's seed-stage status and lean organizational profile at the time of closing. Taken together, the two acquisitions indicate a deliberate effort by Lilly to build redundant and complementary non-viral delivery capabilities across both RNA and DNA modalities. AstraZeneca made a comparable move in March 2025, acquiring EsoBiotec for up to USD 1 billion to access a non-viral RNA-based platform for in vivo CAR-T cell engineering, reflecting broader large-pharma appetite for early-stage non-viral delivery technology.